MelissaAmberBurgessMD

Sarcoma

Assistant Professor of Medicine Division of Hematology/Oncology, Department of Medicine UPMC Hillman Cancer Center University of Pittsburgh School of Medicine

Join to view full profile

Dr. Burgess is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Burgess' full profile

Already have an account?

Office
5115 Centre Avenue
Second Floor
Pittsburgh, PA 15232
Phone+1 412-692-4724

Fax+1 412-692-4705
Is this information wrong?

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2012 - 2015
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Drexel University College of MedicineClass of 2009

Certifications & Licensure

PA State Medical License 2009 - 2024
American Board of Internal Medicine Internal Medicine

Clinical Trials

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Start of enrollment: 2013 Sep 24
Completed
Phase 1, Phase 2
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2017 Jul 03
Completed
Phase 1
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers Start of enrollment: 2018 Jun 15
Terminated
Phase 1, Phase 2
A Study of AL102 in Patients With Progressing Desmoid Tumors Start of enrollment: 2021 Mar 30
Active, not recruiting
Phase 2, Phase 3
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Start of enrollment: 2019 Dec 19
Recruiting
Phase 3
Study of INBRX-109 in Conventional Chondrosarcoma Start of enrollment: 2021 Sep 23
Recruiting
Phase 2
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) Start of enrollment: 2017 Aug 15
Active, not recruiting
Phase 3
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Start of enrollment: 2021 Feb 28
Active, not recruiting
Phase 1
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin Start of enrollment: 2018 Mar 29
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1053 citations
B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung, Tom Wei-Wu Chen, Cheng-Ming Sun
Nature. 2020-01-23
43 citations
Immunotherapeutic Approaches to Sarcoma
Melissa Amber Burgess, Hussein Tawbi
Current Treatment Options in Oncology. 2015-05-15
2 citations
The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.
Irantzu Anzar, Brandon Malone, Pubudu Samarakoon, Ioannis Vardaxis, Boris Simovski
Frontiers in Immunology. 2023-01-01

Lectures

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expan...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Pembrolizumab Makes Inroads in Sarcoma SubtypesNovember 14th, 2017
Pembrolizumab Antitumor Activity Promises Potential for Sarcoma SubtypesNovember 15th, 2016
Immunotherapy Effective Against Some Types of SarcomaJune 6th, 2016
Join now to see all